Recently, the Class 1 innovative drug "UBT251 Injection" , developed by TUL's wholly-owned subsidiary, The United Bio Technology (Hengqin) Co., Ltd., has been successfully included in the list of key varieties of the Greater Bay Area Center for Drug Evaluation and Inspection by the National Medical Products Administration. After being selected, this variety will receive policy support such as "dedicated liaison and priority service" from the Greater Bay Area Center for Drugs, which will help accelerate the drug approval market process and help bring high-quality innovative drugs to patients faster.